|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2900 Ames Crossing Road |
Address2 |
|
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
|
5. Senate ID# 400339576-12
|
||||||||
|
6. House ID# 403630000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: David Root |
Date | 1/21/2020 11:25:59 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 965/S. 340: The Creating and Restoring Equal Access to Equivalent Samples (CREATES Act). Implementation of the e-prescribing provisions of the controlled substances provisions of the SUPPORT Act (P.L. 115-271). S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. S. 2119: The Insulin Price Reduction Act, requires private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs. H.R. 3: Elijah E. Cummings Lower Drugs Costs Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesigns the Medicare Part D drug benefit. H.R. 5304: legislation to amend title XXVII of the Public Health Service Act to require health plan oversight of pharmacy benefit manager services.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 965/S. 340: The Creating and Restoring Equal Access to Equivalent Samples (CREATES Act). Implementation of the e-prescribing provisions of the controlled substances provisions of the SUPPORT Act (P.L. 115-271). S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. S. 2199: The Insulin Price Reduction Act, requires private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs. H.R. 3: Elijah E. Cummings Lower Drugs Costs Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesigns the Medicare Part D drug benefit. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, provisions allowing for the offering of additional prescription drug plans under Medicare Part D. S. 2543: The Prescription Drug Pricing Reduction Act, legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drug. Provisions related to inflation protection and PBM transparency. Medicare Advantage and Part D Drug Pricing Final Rule, (CMS-4180-F), provisions related to pharmacy Direct and Indirect Negotiation and a real-time benefit tool. Outreach and education on pharmacy DIR in Medicare Part D. H.R. 2115: Public Disclosure of Drug Discounts and Real-time Beneficiary Drugs Costs Act, provisions requiring HHS to publish information online about discounts under Medicare Advantage and Part D and requirements related to real-time benefits tool implementation. H.R. 1791: The Payment Commission Data Act of 2019, legislation that would require government commission to receive rebate and other data from PBMs/Part D plans.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Julie |
Cantor-Weinberg |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |